From Health Lab: Study Defines Key Driver of Aggressive Ovarian Cancer
A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.
A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.
Jennifer Brazil, PhD, Assistant Professor of Pathology at Michigan Medicine began her own research laboratory in 2018. She continued to research the mechanisms by which polymorphonuclear neutrophils (PMN) and epithelial glycans can be targeted to alter neutrophil transepithelial migration and neutrophil function under conditions of intestinal inflammation and repair.
Heart failure with reduced ejection fraction (HFrEF), which measures your heart’s ability to pump oxygen-rich blood out to your body, remains a leading cause of death and hospitalization worldwide. Over the last three decades, clinical trials have highlighted the efficacy of four key medication classes- Beta-blockers, angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).